JP2019517475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517475A5 JP2019517475A5 JP2018562088A JP2018562088A JP2019517475A5 JP 2019517475 A5 JP2019517475 A5 JP 2019517475A5 JP 2018562088 A JP2018562088 A JP 2018562088A JP 2018562088 A JP2018562088 A JP 2018562088A JP 2019517475 A5 JP2019517475 A5 JP 2019517475A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- independently selected
- alkyl
- heterocyclyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 139
- 125000000623 heterocyclic group Chemical group 0.000 claims 72
- 229910052739 hydrogen Inorganic materials 0.000 claims 66
- 229910052799 carbon Inorganic materials 0.000 claims 53
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- -1 CN Inorganic materials 0.000 claims 14
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000004452 carbocyclyl group Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000239366 Euphausiacea Species 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 1
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 0 C*C(N1C(*)c2ccccc2)=NN(C(C)=CC=C(C=C)C(c2c(N)[n]cc2)=I[Tl])C1=Cl Chemical compound C*C(N1C(*)c2ccccc2)=NN(C(C)=CC=C(C=C)C(c2c(N)[n]cc2)=I[Tl])C1=Cl 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342441P | 2016-05-27 | 2016-05-27 | |
| US62/342,441 | 2016-05-27 | ||
| PCT/US2017/034613 WO2017205709A1 (en) | 2016-05-27 | 2017-05-26 | Triazolones and tetrazolones as inhibitors of rock |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517475A JP2019517475A (ja) | 2019-06-24 |
| JP2019517475A5 true JP2019517475A5 (enExample) | 2020-07-02 |
| JP6987792B2 JP6987792B2 (ja) | 2022-01-05 |
Family
ID=59009815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562088A Active JP6987792B2 (ja) | 2016-05-27 | 2017-05-26 | Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10562887B2 (enExample) |
| EP (1) | EP3464262B1 (enExample) |
| JP (1) | JP6987792B2 (enExample) |
| KR (1) | KR102457933B1 (enExample) |
| CN (1) | CN109153663B (enExample) |
| ES (1) | ES2781309T3 (enExample) |
| WO (1) | WO2017205709A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37073A (es) | 2016-01-13 | 2017-07-31 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen |
| KR102491994B1 (ko) | 2016-07-07 | 2023-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 스피로락탐 |
| EP3481828B1 (en) | 2016-07-07 | 2020-09-16 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
| WO2018009622A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors |
| ES2829400T3 (es) | 2016-11-30 | 2021-05-31 | Bristol Myers Squibb Co | Inhibidores tricíclicos de Rho cinasa |
| EP3652164B1 (en) | 2017-07-12 | 2023-06-21 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
| US12060341B2 (en) | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| EP3652165B1 (en) | 2017-07-12 | 2021-08-25 | Bristol-Myers Squibb Company | Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure |
| KR102644889B1 (ko) | 2017-07-12 | 2024-03-06 | 브리스톨-마이어스 스큅 컴퍼니 | Rock 억제제로서의 스피로헵타닐 히단토인 |
| TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2023041422A1 (en) | 2021-09-20 | 2023-03-23 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| US20250000083A1 (en) | 2021-11-11 | 2025-01-02 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025076010A1 (en) | 2023-10-01 | 2025-04-10 | Massachusetts Institute Of Technology | Site-selective conjugation of a pharmaceutical agent to an antibody using an affinity peptide |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9420064A (en) | 1993-11-19 | 1997-02-28 | Du Pont | Fungicidal cyclic amides |
| US20010020100A1 (en) * | 1994-06-14 | 2001-09-06 | G.D. Searle & Co. | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders |
| US5607932A (en) * | 1994-07-12 | 1997-03-04 | Janssen Pharmaceutica N.V. | Heterocyclic derivatives of azolones |
| JP3056412B2 (ja) * | 1995-02-17 | 2000-06-26 | 武田薬品工業株式会社 | アゾール化合物およびその用途 |
| TW318841B (enExample) * | 1995-02-17 | 1997-11-01 | Takeda Pharm Industry Co Ltd | |
| AU4675596A (en) | 1995-02-17 | 1996-09-04 | Takeda Chemical Industries Ltd. | Azole compounds, their production and use |
| WO1996036615A1 (en) | 1995-05-16 | 1996-11-21 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| EP1713775A4 (en) | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| JP4846709B2 (ja) * | 2004-03-10 | 2011-12-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ５員複素環で置換されているｍｔｐ阻害性アリールピペリジン若しくはピペラジン |
| TW200612961A (en) | 2004-05-18 | 2006-05-01 | Fmc Corp | Substituted cyclic urea derivatives |
| WO2006019768A1 (en) * | 2004-07-16 | 2006-02-23 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| CN101084201A (zh) * | 2004-12-21 | 2007-12-05 | 詹森药业有限公司 | 用作α2C－肾上腺素能受体拮抗剂的三唑酮、四唑酮和咪唑酮衍生物 |
| US8211919B2 (en) * | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| PE20140572A1 (es) | 2008-06-05 | 2014-05-16 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
| WO2010077582A1 (en) | 2008-12-16 | 2010-07-08 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| US9409868B2 (en) * | 2012-01-24 | 2016-08-09 | H. Lee Moffin Cancer Center and Research Institute, Inc. | Inhibitors of rho associated protein kinases (ROCK) and methods of use |
| WO2014113620A2 (en) | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
| WO2014134391A1 (en) * | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) * | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| ES2634628T3 (es) | 2013-07-02 | 2017-09-28 | Bristol-Myers Squibb Company | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK |
| MX2016008842A (es) * | 2014-01-20 | 2016-11-08 | Hoffmann La Roche | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| JP6779214B2 (ja) * | 2015-01-09 | 2020-11-04 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての環状ウレア |
| EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| UY37073A (es) | 2016-01-13 | 2017-07-31 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen |
| EP3481828B1 (en) | 2016-07-07 | 2020-09-16 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
| WO2018009622A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors |
| KR102491994B1 (ko) | 2016-07-07 | 2023-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 스피로락탐 |
| ES2829400T3 (es) | 2016-11-30 | 2021-05-31 | Bristol Myers Squibb Co | Inhibidores tricíclicos de Rho cinasa |
-
2017
- 2017-05-26 ES ES17728029T patent/ES2781309T3/es active Active
- 2017-05-26 EP EP17728029.4A patent/EP3464262B1/en active Active
- 2017-05-26 US US16/098,978 patent/US10562887B2/en active Active
- 2017-05-26 KR KR1020187037221A patent/KR102457933B1/ko active Active
- 2017-05-26 JP JP2018562088A patent/JP6987792B2/ja active Active
- 2017-05-26 CN CN201780031569.6A patent/CN109153663B/zh active Active
- 2017-05-26 WO PCT/US2017/034613 patent/WO2017205709A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501285A5 (enExample) | ||
| JP2019520396A5 (enExample) | ||
| JP2021501782A5 (enExample) | ||
| JP2019520402A5 (enExample) | ||
| JP2018538304A5 (enExample) | ||
| IL259947A (en) | The troirylhydroxypyrimidinones as apj receptor agonists | |
| JP2019532072A5 (enExample) | ||
| HRP20201927T1 (hr) | PIRIMIDINONI KAO INHIBITORI FAKTORA XIa | |
| JP2020500869A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2019519476A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2016510033A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2012513481A5 (enExample) | ||
| JP2019527682A5 (enExample) | ||
| JP2016505042A5 (enExample) | ||
| SI2906551T1 (en) | Crystalline forms of a factor xia inhibitor | |
| RU2018104092A (ru) | Бициклические лактамы и способы их применения | |
| HRP20161378T1 (hr) | Dihidropiridon kao faktor xia inhibitora | |
| JP2010524896A5 (enExample) | ||
| JP2021535177A5 (enExample) | ||
| JP2012526769A5 (enExample) | ||
| JP2023502458A5 (enExample) |